Congress Weighs Health Transparency Laws Amid Regulatory Ramp-Up

The live question for counsel tracking federal health transparency law and regulation in Q3 2026 is not whether Congress has noticed the issue. It has. Several bipartisan bills remain pending in the 119th Congress, including the Patients Deserve Price Tags Act, and House committees continue to hold hearings on health costs. The harder question is whether any of that work will become enforceable statutory law before the compliance calendar has already moved on.

That distinction matters because CMS is no longer waiting for Congress to settle the architecture. Under the CY 2026 OPPS Final Rule, the agency’s hospital price transparency enforcement ramp-up began on April 1, 2026, with new executive attestation expectations and a more concrete enforcement posture already shaping provider obligations.[1][2]

For legal teams, the result is an awkward but familiar split-screen: statutory proposals may still change the outer boundaries of price transparency, while regulatory enforcement is already asking hospitals to produce files, certify accuracy, and manage penalty exposure.

The Bill To Watch: Patients Deserve Price Tags Act

The Patients Deserve Price Tags Act, introduced as S. 2355 and H.R. 5582, is the most operationally important of the pending transparency bills because it would do more than restate the current hospital price transparency regime. Available bill metadata identifies the measure in both chambers, while secondary analyses describe it as an effort to codify hospital price transparency requirements and expand them beyond hospitals to laboratories, imaging centers, and ambulatory surgical centers.[3][4]

That expansion is the point counsel should not bury under the general phrase “price transparency.” A hospital system with owned imaging assets, a joint-venture ASC portfolio, or affiliated lab operations would not experience this bill as a symbolic codification exercise. It would have to ask which entities are in scope, which data elements must be published, who owns validation, how often files are refreshed, and whether existing hospital transparency workflows can be extended without creating inconsistent disclosures across sites of care.

The penalty language also changes the risk conversation. Mercer’s overview describes the bill as raising penalties for willful violations up to $10 million.[4] That figure should be verified against official bill text before anyone quotes operative language in a board memo, but even as described, it would move the discussion out of the category of tolerable administrative friction and into enterprise compliance risk.

The bill’s appeal is easy to understand: it gives Congress a way to put statutory backing behind transparency obligations that have largely been built through regulation. Its difficulty is also easy to understand. Codification freezes choices that agencies can otherwise revise, and expansion to non-hospital settings forces Congress to decide how much precision belongs in the statute rather than in implementing rules.

Other House Proposals Would Pull Different Compliance Levers

The Patients Deserve Price Tags Act is not the only pending vehicle. The Lower Costs More Transparency Act, H.R. 9393, remains relevant because the available summaries describe a broader package: site-neutral billing provisions, transparency requirements for pharmacy benefit managers, and contract restrictions aimed at anti-steering arrangements.[5][4]

Those provisions would land on different desks. Site-neutral billing affects revenue-cycle modeling and service-line strategy. PBM transparency reaches plan sponsors, payers, and pharmacy benefit contracting. Anti-steering restrictions would require contract review rather than only web-file publication. A single “transparency” label does not make these obligations interchangeable.

The Health Care PRICE Transparency Act, H.R. 267, is narrower but still worth tracking because Congress.gov metadata identifies it as a hospital price transparency bill, and the research materials characterize it as another vehicle to codify hospital transparency rules and add enforcement mechanisms.[6] For counsel, that means the bill may matter even if it does not become the final legislative vehicle; its concepts can migrate into a larger package.

Committee Activity Shows Attention, Not Enactment

There is real congressional activity. The House Energy and Commerce Health Subcommittee held a June 10, 2026 hearing on lowering health care costs, a setting that kept transparency and affordability proposals in the committee conversation.[7] That is not nothing. Hearings create records, test legislative pairings, and show which provisions can survive member scrutiny.

But hearings do not put a compliance date on a client’s calendar. The 2026 legislative calendar is shortened by election-year constraints, and even bipartisan health-cost legislation must compete with appropriations, nominations, campaign timing, and leadership priorities. A bill can be bipartisan, familiar, and still not be enacted by year-end.

The Senate side adds another uncertainty. HFMA’s analysis of a May 2026 HELP Committee field hearing in Louisiana noted that Sen. Bill Cassidy’s May 16, 2026 primary loss created a leadership vacancy that could shift committee dynamics.[8] The practical consequence is not that transparency legislation is dead or revived. It is that counsel should treat HELP Committee timing and succession as unsettled variables rather than as a stable path to enactment.

CMS Has Already Changed The Compliance Posture

While Congress negotiates, CMS has moved into implementation. The CY 2026 OPPS Final Rule’s hospital price transparency changes became enforceable on April 1, 2026, according to law firm analyses tracking the rule’s compliance implications.[1][2] Those analyses also describe new executive attestation requirements, meaning price transparency is no longer only a technical publishing task delegated to a reimbursement analyst or vendor team.

Executive attestation changes internal behavior. Someone senior must be comfortable that the organization’s machine-readable file is complete, accurate, and defensible enough to certify. That pushes legal, compliance, finance, revenue-cycle, managed care, and IT teams into the same room. It also makes weak governance harder to hide behind vendor dependency.

Dentons reported that CMS had issued 519 noncompliance letters in connection with the hospital price transparency regime.[2] Because that figure is being relied on through a secondary legal analysis rather than reproduced here from an independent CMS enforcement dataset, it should be treated as a sourced enforcement indicator, not as a comprehensive public accounting of every agency contact.

Even with that caution, the signal is clear enough for operational planning: CMS is reviewing files, contacting hospitals, and asking leadership to stand behind disclosures. A pending statute may later change penalties or covered entities, but it does not erase the need to comply with the rule now in force.

Where The Pending Bills Could Still Matter

The most important legislative function in 2026 may be durability. If Congress codifies hospital price transparency requirements, a future administration would have less room to dilute or restructure the regime through ordinary rulemaking. That does not make current bills inevitable, but it explains why statutory text matters even when CMS is already active.

Expansion is the second function. CMS hospital rules do not, by themselves, answer how Congress might treat labs, imaging centers, or ASCs. The Patients Deserve Price Tags Act, as described by Mercer, would move transparency obligations into those settings.[4] For a multi-site provider enterprise, that is not an abstract expansion. It can require inventorying entities, identifying payer-specific negotiated rates by location, aligning data feeds, and deciding whether current hospital transparency vendors can handle non-hospital files.

Penalty escalation is the third function. A possible $10 million willful-violation ceiling would affect settlement posture, reserve discussions, board reporting, and the tolerance for leaving questionable data gaps unresolved.[4] The legal task is not to assume that number becomes law. It is to identify which remediation projects become urgent if Congress moves that kind of penalty language into an enacted package.

The Lower Costs More Transparency Act would matter in a different way. Its site-neutral billing, PBM transparency, and anti-steering components would reach contracting and payment structure rather than only consumer-facing disclosure.[5][4] A hospital transparency team cannot absorb that work alone.

The Industry Burden Argument Is Real, But Not Dispositive

Hospitals have not been silent about implementation friction. The American Hospital Association’s June 5, 2026 fact sheet argues from the industry side of the current transparency landscape and is useful because it reflects the compliance burden, operational complexity, and policy concerns hospitals are putting before lawmakers and regulators.[9]

That perspective should be taken seriously in legal advice. Machine-readable files are not self-generating. Contract terms may not map neatly to standardized fields. Payer-specific negotiated rates can depend on service bundles, carve-outs, modifiers, or contracting structures that are difficult to translate for public consumption. Hospitals also have to reconcile transparency work with No Surprises Act operations, revenue-cycle systems, payer negotiations, and patient-estimate workflows.

But burden does not answer the statutory question. Congress can recognize implementation costs and still decide that public disclosure should be mandatory, broader, and backed by larger penalties. A prudent legal assessment separates the argument that a requirement is hard to implement from the question whether it is likely to be imposed or enforced.

What Counsel Should Treat As Real In Q3 2026

The legislative track deserves monitoring, especially the Patients Deserve Price Tags Act and any House package that combines hospital transparency with site-neutral billing, PBM transparency, or anti-steering restrictions. The current bills identify the kinds of obligations Congress may be willing to harden into statute: broader covered entities, stronger enforcement, and less tolerance for opaque payer-provider arrangements.

The regulatory track deserves budget. Hospitals subject to the CMS rule should not delay file remediation, executive attestation processes, or internal audit work on the theory that Congress may later replace the current framework. The active rule is already shaping enforcement expectations, and a future statute is more likely to add to the compliance map than to excuse present gaps.

For non-hospital providers, the immediate question is preparation rather than full implementation. Labs, imaging centers, and ASCs should watch the Patients Deserve Price Tags Act because expansion to those settings would require scoping work that cannot be completed overnight. A legal team can begin by identifying relevant entities, contracting data sources, vendor dependencies, and governance owners without assuming enactment.

For payers and PBMs, the Lower Costs More Transparency Act is the cleaner warning sign. Contract restrictions and PBM transparency are not solved by hospital file compliance. They require contract inventory, claims-data capability, plan-sponsor communication, and anti-steering review.

The calibrated advice is therefore narrow but firm: track the bills, do not forecast enactment with confidence, and do not let legislative uncertainty become an excuse for underinvesting in the CMS compliance work already underway.

References

1. CY 2026 Hospital Outpatient Prospective Payment System and Ambulatory Surgical Center Payment System Final Rule, Centers for Medicare & Medicaid Services.
2. CMS price transparency enforcement analysis, Dentons.
3. S.2355 - Patients Deserve Price Tags Act, Congress.gov.
4. Patients Deserve Price Tags Act and federal health transparency legislation overview, Mercer.
5. H.R.9393 - Lower Costs More Transparency Act, Congress.gov.
6. H.R.267 - Health Care PRICE Transparency Act, Congress.gov.
7. House Energy and Commerce Health Subcommittee hearing coverage on lowering health care costs, Legis1.com, June 10, 2026.
8. Analysis of HELP Committee field hearing in Louisiana and Sen. Cassidy primary loss, Healthcare Financial Management Association, May 2026.
9. Hospital Price Transparency Fact Sheet, American Hospital Association, June 5, 2026.